Indicator Details: Percentage with Albuminuria or eGFR > 15 Who Were Aware of Their Diseasea
Data Sources
 
Stratification and Year Choices:

  Source
  • NHANES

  View Data By:
  Chart Format


+ View Data Table

Footnotes:
a Albuminuria defined by albumin:creatinine ratio obtained from spot urine sample: microalbuminuria, 30-299 mg/g; macroalbuminuria, ≥300 mg/g.




In 1999-2014, <7% of those with eGFR ≥60 ml/min/1.73 m² with albuminuria (single random measurement) were aware of having CKD. Reported awareness was estimated to be higher for those with stage 3B (eGFR 30-45) at 28% compared to those with CKD stage 3A (eGFR 45-59) at 10%. For stage 4 (eGFR 15-29), about half reported being aware of their disease.

Those with evidence of albuminuria, particularly an albumin:creatinine ratio ≥300 mg/g (macroalbuminuria), were generally more likely to be aware of their CKD condition (19% in 1999-2004 to 21% in 2011-2014).
Chart Explanation: For all study years combined (1999-2014), overall awareness of CKD was 6.4%. As expected, awareness increased with severity or stage of CKD. However, just over half of participants (52.5%) with stage 4 (- the most severe stage prior to end-stage renal disease - reported being told by their physician that they had weak or failing kidneys. Fewer than 30% of stage 3 participants were aware of their disease, although the proportion was substantially higher for those with eGFR 30-44 than those with eGFR 45-59 ml/min/1.73 m² (27.7% vs. 9.8%). Among those with eGFR <90 and >30 ml/min/1.73 m², macroalbuminuria versus microalbuminuria was associated with greater awareness. For example, among those with eGFR 30-44 ml/min/1.73 m², awareness was 21.5% among those with microalbuminuria, while 44.8% of those with macroalbuminuria reported being aware, respectively.

In observance of albuminuria over time, microalbuminuria remained low with 5.2% reporting awarenss in 1999-2004 to 6.5% in 2011-2014. As noted, awareness was more likely in those with micro albuminuria (19.2% in 1999-2004 to 20.7% in 2011-2014). The trends for reported awareness of CKD were not significant for either stages of microalbuminuria.
The National Health and Nutrition Examination Survey (NHANES) is a nationally representative, cross-sectional survey that is currently conducted every 2 years by the Centers for Disease Control and Prevention's National Center for Health Statistics to examine disease prevalence and trends over time in noninstitutionalized U.S. civilian residents.

The survey consists of a standardized in-home interview and a physical examination and blood and urine collection at a mobile examination center (MEC). Here we examined data from the 1999-2000, 2001-2002, 2003-2004, 2005-2006, 2007-2008, 2009-2010, 2011-2012, and 2013-2014 NHANES. Awareness of CKD was defined as a “yes” response to the question “Have you ever been told by a health care provider you have weak or failing kidneys (excluding kidney stones, bladder infections, or incontinence)?” during the interview. CKD was diagnosed by laboratory testing and defined as an eGFR of ≥60 ml/min/1.73 m² and the presence of albuminuria (first single measurement of albumin: creatinine ratio from random spot urine) or by eGFR alone for CKD stage 3 or 4 (stage 5 was excluded).
FieldData
Description of MeasureAwareness of CKD among those with kidney disease diagnosed by laboratory testing
Data SourceNCHS
Type of Data SourcePublic
Data SetNHANES
Health Care System DataNo
Regional or National?National
Demographic GroupNon-institutionalized U.S. residents aged 20+ years
NumeratorParticipants with CKD who have been told they have weak or failing kidneys
DenominatorParticipants with CKD
Definition of CKDStage 1, eGFR > 90 ml/min/1.73 m² and presence of single albuminuria; Stage 2, eGFR 60-89 ml/min/1.73 m² and presence of single albuminuria; Stage 3, eGFR 30-59 ml/min/1.73 m²; Stage 4, 15-29 ml/min/1.73 m²; Stage 5, excluded
Glomerular filtration rateEstimated using CKD-EPI equation for calibrated creatinine: eGFR=141 x [min(calibrated serum creatinine in mg/dL) /κ, 1)]α x [max(calibrated serum creatinine in mg/dL/κ, 1)]κ  x 0.993age x (1.018 if female) x (1.159 if NH Black)
κ = 0.7 if female, and 0.9 if male
α = -0.329 if female, and -0.411 if male
ProteinuriaUrinary albumin-to-creatinine ratios of 30-299 mg/g (microalbuminuria) and >300 mg/g (macroalbuminuria); pregnant/menstruating women excluded
Primary Data Source Indicatorkiq022/kiq010: “Have you ever been told by a doctor or health professional that you have weak or failing kidneys (excluding kidney stones, bladder infections, or incontinence)?” yes/no
Primary Indicator Method of MeasurementQuestionnaire (interviewer-administered)
Secondary (1) Variablelbxscr: Serum creatinine
Secondary (1) Indicator Method of MeasurementExamination/Laboratory
Secondary (2) Variableridageyr: Age in years
Secondary (2) Indicator Method of MeasurementQuestionnaire (interviewer-administered)
Secondary (3) Variableridgendr: Gender
Secondary (3) Indicator Method of MeasurementQuestionnaire (interviewer-administered)
Secondary (3) from Medical Record? No
Secondary (4) Data Source Indicatorridreth1: Race/ethnicity
Secondary (4) Indicator Method of Measurement Questionnaire (interviewer-administered)
Secondary (5) Data Source Indicatorurxuma: Urine albumin
Secondary (5) Indicator Method of Measurement Examination/lab
Secondary (5) Data Source Indicatorurxucr: Urine creatinine
Secondary (5) Indicator Method of Measurement Examination/lab
Frequency of Measurement (Primary)Once (cross-sectional)
U.S. Region Covered by Primary VariableAll
Period Currently Available1999–2014
Pending Data2015-2016
Additional Data Items of InterestStage of CKD, year, other stratification variables of interest (diabetes by self-report, hypertension by self-report)
Limitations of IndicatorProteinuria can only be assessed from a one-time cross-sectional measurement in 1999-2008; two measurements only in 2009-2010, including first random and second first-morning void ~2 weeks after MEC exam; participants who have been told they have proteinuria may not answer yes
Analytic ConsiderationsAppropriate NHANES survey weights must be used for all analyses; creatinine measurements must be calibrated for NHANES years 1999-2000 and 2005-2006; if 2007-2008 data are combined with 1999-2006 data, the earlier data on urinary creatinine must be corrected; many variable names differ across surveys; if SE 30% or more of estimate, must suppress estimates and report as “low precision”; second urine albumin and creatinine measurements only available in 2009-2010 and not for 2011+
Suggested Citation:
Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System—United States.
website. http://www.cdc.gov/ckd